137 related articles for article (PubMed ID: 29987132)
1. Considerations for development of therapies for cutaneous neurofibroma.
Verma SK; Riccardi VM; Plotkin SR; Weinberg H; Anderson RR; Blakeley JO; Jarnagin K; Lee J
Neurology; 2018 Jul; 91(2 Suppl 1):S21-S30. PubMed ID: 29987132
[TBL] [Abstract][Full Text] [Related]
2. The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities.
Brosseau JP; Pichard DC; Legius EH; Wolkenstein P; Lavker RM; Blakeley JO; Riccardi VM; Verma SK; Brownell I; Le LQ
Neurology; 2018 Jul; 91(2 Suppl 1):S14-S20. PubMed ID: 29987131
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous neurofibromas: Current clinical and pathologic issues.
Ortonne N; Wolkenstein P; Blakeley JO; Korf B; Plotkin SR; Riccardi VM; Miller DC; Huson S; Peltonen J; Rosenberg A; Carroll SL; Verma SK; Mautner V; Upadhyaya M; Stemmer-Rachamimov A
Neurology; 2018 Jul; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130
[TBL] [Abstract][Full Text] [Related]
4. Creating a comprehensive research strategy for cutaneous neurofibromas.
Blakeley JO; Wolkenstein P; Widemann BC; Lee J; Le LQ; Jackson R; Stathis M; Verma SK
Neurology; 2018 Jul; 91(2 Suppl 1):S1-S4. PubMed ID: 29987129
[TBL] [Abstract][Full Text] [Related]
5. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
Maguiness S; Berman Y; Rubin N; Dodds M; Plotkin SR; Wong C; Moertel C;
Neurology; 2021 Aug; 97(7 Suppl 1):S25-S31. PubMed ID: 34230204
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial design for cutaneous neurofibromas.
Cannon A; Jarnagin K; Korf B; Widemann BC; Casey D; Ko HS; Blakeley JO; Verma SK; Pichard DC
Neurology; 2018 Jul; 91(2 Suppl 1):S31-S37. PubMed ID: 29987133
[TBL] [Abstract][Full Text] [Related]
7. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
Cannon A; Pichard DC; Wolters PL; Adsit S; Erickson G; Lessing AJ; Li P; Narmore W; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S15-S24. PubMed ID: 34230202
[TBL] [Abstract][Full Text] [Related]
8. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
[TBL] [Abstract][Full Text] [Related]
9. Topical sirolimus as an effective treatment for a deep neurofibroma in a patient with neurofibromatosis type I.
Malhotra N; Levy JMS; Fiorillo L
Pediatr Dermatol; 2019 May; 36(3):360-361. PubMed ID: 30828862
[TBL] [Abstract][Full Text] [Related]
10. Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research.
Wallis D; Stemmer-Rachamimov A; Adsit S; Korf B; Pichard D; Blakeley J; Sarin KY;
Neurology; 2021 Aug; 97(7 Suppl 1):S42-S49. PubMed ID: 34230199
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey.
Guiraud M; Bouroubi A; Beauchamp R; Bocquet A; Grégoire JM; Rauly-Lestienne I; Blanco I; Wolkenstein P; Schmitt AM
Orphanet J Rare Dis; 2019 Dec; 14(1):286. PubMed ID: 31801570
[TBL] [Abstract][Full Text] [Related]
12. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.
Nguyen HTL; Kohl E; Bade J; Eng SE; Tosevska A; Al Shihabi A; Tebon PJ; Hong JJ; Dry S; Boutros PC; Panossian A; Gosline SJC; Soragni A
Cell Rep Methods; 2024 May; 4(5):100772. PubMed ID: 38744290
[TBL] [Abstract][Full Text] [Related]
13. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
Rhodes SD; McCormick F; Cagan RL; Bakker A; Staedtke V; Ly I; Steensma MR; Lee SY; Romo CG; Blakeley JO; Sarin KY
J Invest Dermatol; 2023 Aug; 143(8):1358-1368. PubMed ID: 37245145
[TBL] [Abstract][Full Text] [Related]
14. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials.
Thalheimer RD; Merker VL; Ly KI; Champlain A; Sawaya J; Askenazi NL; Herr HP; Da JLW; Jordan JT; Muzikansky A; Pearce EM; Sakamoto FH; Blakeley JO; Anderson RR; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S32-S41. PubMed ID: 34230197
[TBL] [Abstract][Full Text] [Related]
15. Distinct Transcriptional Profiles in the Different Phenotypes of Neurofibroma from the Same Subject with Neurofibromatosis 1.
Wang WN; Koguchi-Yoshioka H; Nimura K; Watanabe R; Tanemura A; Fujimoto M; Wataya-Kaneda M
J Invest Dermatol; 2024 Jan; 144(1):133-141.e4. PubMed ID: 37301319
[TBL] [Abstract][Full Text] [Related]
16. Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.
Oliveira LB; Geller M; Cunha KS; Santos A; Bernacchi A; Rubenstein AE; Takirambudde S; Mezitis S; de Almeida Ito Brum C; Darrigo LG; Ribeiro MG
Heliyon; 2021 Mar; 7(3):e06518. PubMed ID: 33817379
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronan in intra-operative edema of NF1-associated neurofibromas.
Hagel C; Behrens T; Prehm P; Schnabel C; Glatzel M; Friedrich RE
Neuropathology; 2012 Aug; 32(4):406-14. PubMed ID: 22129111
[TBL] [Abstract][Full Text] [Related]
18. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sarin KY; Bradshaw M; O'Mara C; Shahryari J; Kincaid J; Kempers S; Tu JH; Dhawan S; DuBois J; Wilson D; Horwath P; de Souza MP; Powala C; Kochendoerfer GG; Plotkin SR; Webster GF; Le LQ
Sci Adv; 2024 May; 10(18):eadk4946. PubMed ID: 38691597
[TBL] [Abstract][Full Text] [Related]
19. [Treatment and progress of cutaneous neurofibroma].
Zhu B; Wei C; Wang W; Gu B; Li Q; Wang Z
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2022 Sep; 36(9):1064-1071. PubMed ID: 36111466
[TBL] [Abstract][Full Text] [Related]
20. Floret-like multinucleated giant cells in a neurofibromatosis type 1-associated neurofibroma.
Swick BL
Am J Dermatopathol; 2008 Dec; 30(6):632-4. PubMed ID: 19033946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]